Ann: Trading Halt, page-14

Hi Steini, I love some of your contributions Mate. But please stop the cross promotion firing off Paul Hoppers companies in every post. Each one has a different approach to cancer treatments by molecule, modality, cancer type etc. Best to keep commentary relevant to each company, they do not need to be pigeon holed together. And, It was never going to be another raise.

I'm no expert but combining CHM1101 with CF33 will not provide the benefit as it would with a CD19 Car-T. CF33 is designed to force an expression of the CD19 target in solid tumours so CD19 targeted therapies (some already FDA approved for blood cancer) can then work as a destroying machine on solid tumours. CHM1101 targets the MMP2 target. Now what would be nice is if Yumen Fong could design an Oncarlytic virus to force an over expression of MMP2 in other Tumours and combine with CHM-1101 when and if it works. Believe it or not the herpes simplex virus expresses MMP2, this could be a hard sell to patients.

Anyhow, let's hope it is good news.